Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 199–200
HOS-215014 · Präparat HOS-155350
199 MedDRA system organ Very common adverse Common adverse reactions classes reactions Metabolism and nutrition Anorexia disorders Nervous system disorders Peripheral sensory neuropathy Peripheral motor neuropathy (G3/4: 0.8%) (G3/4: 2.5%) Cardiac disorders Arrhythmia (no severe) Vascular disorders Hypotension Gastrointestinal disorders Nausea (G3/4: 3.3%); Constipation Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%); Diarrhoea (G3/4: 1.7%) Skin and subcutaneous tissue Alopecia; Nail disorders (severe: 0.8%) disorders Skin reaction (G3/4: 0.8%) Musculoskeletal and Myalgia connective tissue disorders General disorders and Asthenia (severe: 12.4%); administration site conditions Fluid retention (severe: 0.8%); Pain Investigations G3/4 Blood bilirubin increased (< 2%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 06635f8030eb5a82ccc39badfa2b57b91446ce33f62ff3fdcd128c75c47aa0cd · Zeichen 10861–12270 im Abschnitt